Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Before investing all your savings, evaluate your financial goals and risk tolerance. Make informed decisions to safeguard your future.
23,659 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Costco crossed the $1,000 mark in early May 2026, prompting fresh debate about selling in May—even for blue-chip equi...
A stationary Knight Rider replica at a Chicago-area museum received a $50 speeding ticket in Brooklyn, raising questi...
Oklo stock dropped today after a new analyst note drew cautious lines around valuation and timing for its small modul...
Inflation is pushing up the price tag for Memorial Day cookouts, with beef and produce leading the gains. This report...
A smaller social media platform is trading under $30 while delivering double-digit revenue growth and robust cash flo...
The Pennsylvania House approved HB 2186, a by-right ADU reform, in a bipartisan vote and sent the bill to the Senate....
A once-high-flying growth stock tumbled 84% from its peak. This guide explains how to separate a genuine opportunity ...
NVIDIA shares pulled back amid an AI sector-wide retreat, but a growing data-center footprint and a record order book...
Two 2x MicroStrategy ETFs, MSTX and MSTU, are under renewed scrutiny as volatility tests the funds' synthetic exposur...
Taiwan Semiconductor Manufacturing Co. is trading at a valuation many investors describe as dirt cheap as AI-driven d...
A bold government push is reshaping quantum tech and investing. Learn which three big stocks are positioned to win, a...